Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-10
2007-04-10
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S300000, C514S310000, C544S293000, C546S122000, C546S143000
Reexamination Certificate
active
10997734
ABSTRACT:
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 3406199 (1968-10-01), Weber et al.
patent: 4611004 (1986-09-01), Ackermann et al.
patent: 4755594 (1988-07-01), Bridges et al.
patent: 5281625 (1994-01-01), Zipplies et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5631282 (1997-05-01), Goetz
patent: 5646162 (1997-07-01), Müller et al.
patent: 5670504 (1997-09-01), Bochis et al.
patent: 5679705 (1997-10-01), Baker et al.
patent: 5696156 (1997-12-01), Baker et al.
patent: 5900415 (1999-05-01), Peterson et al.
patent: 5952363 (1999-09-01), Kristiansen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6426365 (2002-07-01), Shinkai et al.
patent: 6455550 (2002-09-01), Chen et al.
patent: 6632836 (2003-10-01), Baker et al.
patent: 6660742 (2003-12-01), Lee
patent: 6953792 (2005-10-01), Castro Pineiro et al.
patent: 2004/0014748 (2004-01-01), Grutzmann et al.
patent: 2004/0171642 (2004-09-01), Pineiro et al.
patent: WO 00/01389 (2000-01-01), None
Balser, J.R. et al., “Suppression of Time-Dependent Outward Current in Guinea Pig Ventricular Myocytes: Actions of Quinidine and Amiodarone”, Circulation Research, vol. 69, No. 2, pp. 519-529 (1991).
Bowlby, M.R. et al., “Block of Cloned Voltage-Gated Potassium Channels by the Second Messenger Diacylgycerol Independent of Protein Kinase C”, Journal of Neurophysiology, vol. 73, No. 6, pp. 2221-2229 (1995).
Chandy, K.G. et al., “Voltage-Gated Potassium Channels are Required for Human T Lymphocyte Activation”, J. Exp. Med., vol. 160, pp. 369-385 (1984).
DeCoursey, T.E. et al., “Voltage-gated K+channels in human T lymphocytes: a role in mitogenesis?”, Nature, vol. 307, pp. 465-468 (1984).
Doupnik, C.A. et al., “The inward rectifier potassium channel family”, Current Opinion in Neurobiology, vol. 5, pp. 268-277 (1995).
Fedida, D. et al., “Identity of a Novel Delayed Rectifier Current From Human Heart With a Cloned K+Channel Current”, Circulation Research, vol. 73, No. 1, pp. 210-216 (1993).
Greene, T.W. et al., Protective Groups in Organic Synthesis, Second Edition, John Wiley and Sons, publ., pp. ix-x (table of contents) (1991).
Grissmer, S. et al., “Pharmacological Characterization of Five Cloned Voltage-Gated K+Channels, Types Kv1.1, 1.2, 1.3, 1.5, and 3.1, Stably Expressed in Mammalian Cell Lines”, Molecular Pharmacology, vol. 45, pp. 1227-1234 (1994).
Hondeghem, L.M., “Development of Class III Antiarrhythmic Agents”, Journal of Cadiovascular Pharmacology, vol. 20, Suppl. 2, S17-S22 (1992).
Kalman, K. et al., “Genomic Organization, Chromosomal Localization, Tissue Distribution, and Biophysical Characterization of a Novel MammalianShaker-related Voltage-gated Potassium Channel, Kv1.7”, The Journal of Biological Chemistry, vol. 273, No. 10, pp. 5851-5857 (1998).
Leonard, R.J. et al., “Selective blockers of voltage-gated K+channels depolarize human T lymphocytes: Mechanism of the antiproliferative effect of charybdotoxin”, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 10094-10098 (1992).
Lin, S.C. et al., “Voltage-gated Potassium Channels Regulate Calcium-dependent Pathways Involved in Human T Lymphocyte Activation”, J. Exp. Med., vol. 177, pp. 637-645 (1993).
Nademanee, K., “The Amiodarone Odyssey”, J. Am. Coll. Cardiol., vol. 20, No. 5, pp. 1063-1065 (1992).
Petersen, K.R. et al., “Expression environment determines K+current properties: Kv1 and Kv4 α-subunit-induced K+currents in mammalian cell lines and cardiac myocytes”, Pflugers Arch.—Eur. J. Physiol., vol. 437, pp. 381-392 (1999).
Price, M. et al., “Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes”, Proc. Natl. Acad. Sci. USA, vol. 86, pp. 10171-10175 (1989).
Roden, D.M., “Current Status of Class III Antiarrhythmic Drug Therapy”, The American Journal of Cardiology, vol. 72, pp. 44B-49B (1993).
Sanguinetti, M.C. et al.,, “Two Components Of Cardiac Delayed Rectifier K+Current: Differential Sensitivity to Block by Class III Antiarrhythmic Agents”, J. Gen. Physiol., vol. 96, pp. 195-215 (1990).
Singh, B.N. et al., “A third class of anti-arrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3747”, Br. J. Pharmac., vol. 39, pp. 675-687 (1970).
Singh, B.N. et al., “The effect of amiodarone, A new anti-anginal drug, on cardiac muscle”, Br. J. Pharmac., vol. 39, pp. 657-667 (1970).
Snyders, D.J. et al., “A Rapidly Activating and Slowly Inactivating Potassium Channel Cloned from Human Heart: Functional Analysis after Stable Mammalian Cell Culture Expression”, J. Gen. Physiol., vol. 101, pp. 513-543 (1993).
Swanson, R. et al., “Cloning and Expression of cDNA and Genomic Clones Encoding Three Delayed Rectifier Potassium Channels in Rat Brain”, Neuron, vol. 4, pp. 929-939 (1990).
Wang, Z. et al., “Sustained Depolarization-Induced Outward Current in Human Atrial Myocytes: Evidence for a Novel Delayed Rectifier K+Current Similar to Kv1.5 Cloned Channel Currents”, Circulation Research, vol. 73, No. 6, pp. 1061-1076 (1993).
Yang, T. et al., “Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers”, British Journal of Pharmacology, vol. 115, pp. 267-274 (1995).
Vaughan Williams, EM, Classification of Anti-Arrhythmic Drugs, Sandoe E., Flensted-Jensen E., Olesen K., eds., Cardiac Arrhythmias, Sodertaljie, Swden: AB Astra, 1971, 449-472.
Shinkai, H. et al., “Bis(2-(Acylamino)phenyl) Disulfides . . . ”, Journal of Med. Chem., vol. 43, No. 19, pp. 3566-3572 (2000).
Beaudoin Serge
Finlay Heather
Gross Michael F.
Jeon Yoon T.
Lloyd John
Bogie Terrence J.
Bristol--Myers Squibb Company
Freistein Andrew B.
Icagen Inc.
Saeed Kamal A.
LandOfFree
Cycloalkyl inhibitors of potassium channel function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkyl inhibitors of potassium channel function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkyl inhibitors of potassium channel function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3762084